Related Experiment Video
Updated: Jun 29, 2026

Rapid Glyco-Qualitative Assessment of Recombinant Proteins Using a Fully Automated System
Published on: June 28, 2024
Recognition of galactan components of pectin by galectin-3
A Patrick Gunning1, Roy J M Bongaerts, Victor J Morris
1Institute of Food Research, Norwich Research Park, Colney, Norwich NR4 7UA, UK. patrick.gunning@bbsrc.ac.uk
Abstract:
It has been reported that modified forms of pectin possess anticancer activity. To account for this bioactivity, it has been proposed that fragments of pectin molecules can act by binding to and inhibiting the various roles of the mammalian protein galectin 3 (Gal3) in cancer progression and metastasis. Despite this clear molecular hypothesis and evidence for the bioactivity of modified pectin, the structural origins of the "bioactive fragments" of pectin molecules are currently ill defined. By using a combination of fluorescence microscopy, flow cytometry, and force spectroscopy, it has been possible to demonstrate, for the first time, specific binding of a pectin galactan to the recombinant form of human Gal3. Present studies suggest that bioactivity resides in the neutral sugar side chains of pectin polysaccharides and that these components could be isolated and modified to optimize bioactivity.
Insights
Modified pectin fragments show anticancer potential by inhibiting galectin 3 (Gal3). Researchers identified specific pectin galactan binding to Gal3, suggesting neutral sugar side chains hold bioactivity for cancer therapy development.
Area of Science:
- Biochemistry
- Molecular Biology
- Carbohydrate Chemistry
Background:
- Modified pectin exhibits anticancer properties, potentially by targeting galectin 3 (Gal3).
- The precise structural elements of pectin responsible for this bioactivity remain unclear.
- Galectin 3 plays a critical role in cancer progression and metastasis.
Purpose of the Study:
- To elucidate the structural basis of pectin's anticancer activity.
- To demonstrate direct binding between pectin components and galectin 3.
- To identify specific pectin structures that can be optimized for therapeutic use.
Main Methods:
- Utilized fluorescence microscopy to visualize interactions.
- Employed flow cytometry for quantitative analysis.
- Applied force spectroscopy to probe binding mechanics.
Main Results:
- Confirmed specific binding between a pectin galactan and recombinant human galectin 3.
- Provided the first direct evidence of this molecular interaction.
- Indicated that neutral sugar side chains of pectin are key to bioactivity.
Conclusions:
- Pectin's anticancer activity is linked to the binding of its neutral sugar side chains to galectin 3.
- These specific side chains represent a promising target for developing novel anticancer agents.
- Isolation and modification of these pectin components could enhance therapeutic efficacy.
Related Concept Videos
Cellulose and Pectic Polysaccharides
As a cell matures, its cell wall specializes according to its type. For example, the parenchyma cells of...
Cell Adhesion in Plants
Pectins are complex heteropolymers mainly composed of negatively-charged α-D-glucopyranosyl uronic acid and some neutral glycosyl residues such as α-L-rhamnopyranose, α-L-arabinofuranose, and...
Proteoglycans
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Selectins
Matrix Proteoglycans and Glycoproteins

